Diego Dasilva, MD
Dermatology · Virginia Beach, VANPI 1912499047
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $711,098 of the $1,080,381 with a category attached, or 65.8%. It is spread thinly across 32 manufacturers, the largest accounting for just 18.3%. 2025 is the largest year on record at $654,775, more than ten times the $1,027 reported in 2022. Among dermatology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,758 payments — averaging $614.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$198K
- Sanofi$190K
- Galderma Laboratories, L.p.$162K
- Pfizer$129K
- LEO Pharma Inc.$101K
- Arcutis Biotherapeutics, Inc.$90K
- plus $211K from 26 others
What the payments were for
- Consulting fees$242,40522%
- Speaking & faculty fees$711,09866%
- Travel & lodging$87,8698%
- Food & beverage$38,0694%
- Education$9390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 306 | $197,754 |
| Sanofi | 154 | $190,168 |
| Galderma Laboratories, L.p. | 216 | $162,134 |
| Pfizer | 138 | $128,732 |
| LEO Pharma Inc. | 171 | $101,081 |
| Arcutis Biotherapeutics, Inc. | 151 | $89,791 |
| UCB, Inc. | 110 | $84,813 |
| Organon | 41 | $39,786 |
| Verrica Pharmaceuticals Inc. | 29 | $24,735 |
| Lilly USA, LLC | 45 | $18,344 |
| Johnson & Johnson | 58 | $11,626 |
| Incyte Corporation | 36 | $9,995 |
| Dermavant Sciences, Inc. | 43 | $7,580 |
| Novartis | 32 | $4,513 |
| Kowa Pharmaceuticals America, Inc. | 3 | $3,700 |
| Regeneron Healthcare Solutions, Inc. | 59 | $1,840 |
| E.r. Squibb & Sons, L.L.C. | 89 | $1,762 |
| Amgen | 29 | $708 |
| Sun Pharmaceutical Industries Inc. | 13 | $397 |
| Merz North America, Inc. | 4 | $185 |
| Boehringer Ingelheim | 7 | $160 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $126 |
| Regeneron | 2 | $75 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Janssen Scientific Affairs, LLC | 4 | $71 |
| Convatec Inc. | 2 | $49 |
| Fresenius Kabi USA, LLC | 3 | $43 |
| LNHC, Inc | 2 | $41 |
| Kerecis Limited | 1 | $34 |
| Springworks Therapeutics, Inc. | 1 | $28 |
| Biofrontera Inc. | 1 | $21 |
| Revance Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,080,381 in reported general payments places this provider in the 95th percentile of 396 dermatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 19 | $395,084 |
| Cosentyx Unoready PenSecukinumab | 12 | $173,309 |
| RinvoqUpadacitinib | 27 | $172,635 |
| Dupixent PenDupilumab | 35 | $150,056 |
| AdbryTralokinumab-Ldrm | 15 | $62,484 |
| ZoryveRoflumilast | 20 | $21,373 |
| Clobetasol Propionate | 271 | $11,389 |
| Tretinoin | 59 | $4,410 |
| Tacrolimus | 17 | $3,325 |
| Triamcinolone Acetonide | 200 | $3,172 |
| Ketoconazole | 158 | $3,007 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 36 | $2,434 |
| Dutasteride | 51 | $2,000 |
| Clindamycin-Benzoyl PeroxideClindamycin Phos/Benzoyl Perox | 15 | $1,830 |
| Doxepin Hcl | 51 | $1,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $197,754 | $172,63527 claims |
| LEO Pharma Inc.Adbry | $101,081 | $62,48415 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $89,791 | $21,37320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 396 dermatology providers in Virginia.
Other dermatology in Virginia Beach
- Cyndi Torosky TommasoVirginia Beach$717K
- Tara Buehler BotaVirginia Beach$21K
- Kimberly SoderbergVirginia Beach$12K
- Naiem IssaVienna$2M
- Saurabh SinghFairfax$1.7M
- Vishal PatelLeesburg$719K
- Daniel HurdBlacksburg$545K
- Jonathan SchreiberNorfolk$330K
- Robert BaerSuffolk$303K
- David PariserNorfolk$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.